[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Esperion Theraptc (ESPR)

Esperion Theraptc (ESPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 805,678
  • Shares Outstanding, K 257,405
  • Annual Sales, $ 403,140 K
  • Annual Income, $ -22,680 K
  • EBIT $ 76 M
  • EBITDA $ 79 M
  • 60-Month Beta 0.91
  • Price/Sales 2.00
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 29.95% (+3.25%)
  • Historical Volatility 140.42%
  • IV Percentile 2%
  • IV Rank 1.92%
  • IV High 363.95% on 05/13/25
  • IV Low 23.42% on 05/04/26
  • Expected Move (DTE 3) 0.15 (4.89%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 6,929
  • Volume Avg (30-Day) 3,637
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 98,657
  • Open Int (30-Day) 91,853
  • Expected Range 2.98 to 3.28

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.02
  • Number of Estimates 3
  • High Estimate $0.02
  • Low Estimate $-0.06
  • Prior Year $-0.02
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.80 +73.89%
on 04/29/26
3.18 -1.57%
on 05/06/26
+0.96 (+44.24%)
since 04/10/26
3-Month
1.80 +73.89%
on 04/29/26
3.68 -15.06%
on 02/18/26
-0.33 (-9.54%)
since 02/11/26
52-Week
0.69 +351.99%
on 05/15/25
4.18 -25.03%
on 01/08/26
+2.33 (+292.13%)
since 05/09/25

Most Recent Stories

More News
Esperion's Post-Acquisition Quarter Tests Whether Integration Pace Matches Revenue Momentum

Barchart Research What to Expect from ESPR Earnings ESPR Generated May 6, 2026 Current Price $3.15 EPS Estimate $$-0.04 Consensus Rating Hold Average Move 9.90% Esperion's Post-Acquisition Quarter Tests...

ESPR : 3.13 (-0.32%)
SHAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--ESPR, SILA, CRBG, and EQH

NEW YORK , May 6, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders...

ESPR : 3.13 (-0.32%)
CRBG : 26.34 (-3.55%)
EQH : 40.99 (-3.78%)
SILA : 30.55 (-0.10%)
Are ESPR, GBTG, MDV, ACR Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

ESPR : 3.13 (-0.32%)
ACR : 21.95 (-2.88%)
MDV : 17.77 (-1.11%)
GBTG : 9.39 (-0.63%)
Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Esperion Therapeutics...

ESPR : 3.13 (-0.32%)
Shareholder Alert: Ademi LLP investigates whether Esperion Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders

MILWAUKEE , May 1, 2026 /PRNewswire/ -- Ademi LLP is investigating Esperion (NASDAQ: ESPR) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction...

ESPR : 3.13 (-0.32%)
ESPR Stock Alert: Halper Sadeh LLC is Investigating Whether Esperion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transaction may contain terms that...

ESPR : 3.13 (-0.32%)
Esperion to be Acquired by ARCHIMED

Esperion shareholders to receive $3.16 per share in cash at closing, plus the right to participate in up to $100 million in aggregate contingent milestone payments Represents total equity value of...

ESPR : 3.13 (-0.32%)
Esperion to Report First Quarter 2026 Financial Results on May 7

ANN ARBOR, Mich., April 23, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2026 financial results before the market opens on Thursday, May 7, 2026. Following...

ESPR : 3.13 (-0.32%)
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

–  Enbumyst, First and Only FDA-Approved Nasal Spray Loop Diuretic Now Integrated into Esperion’s Cardiovascular Franchise, Anticipated to Drive Portfolio Expansion, Commercial Leverage, and Continued...

ESPR : 3.13 (-0.32%)
Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference

ANN ARBOR, Mich., March 31, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 25 th Annual Needham Virtual Healthcare Conference...

ESPR : 3.13 (-0.32%)

Business Summary

Esperion Therapeutics, Inc. is a pharmaceutical company focused on the development of oral lipid-management treatments for cardiovascular diseases caused by elevated levels of LDL-C (bad cholesterol).

See More

Key Turning Points

3rd Resistance Point 3.18
2nd Resistance Point 3.16
1st Resistance Point 3.15
Last Price 3.13
1st Support Level 3.12
2nd Support Level 3.10
3rd Support Level 3.09

See More

52-Week High 4.18
Last Price 3.13
Fibonacci 61.8% 2.84
Fibonacci 50% 2.43
Fibonacci 38.2% 2.02
52-Week Low 0.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.